V501 Phase II Immunogenicity Study in Females Aged 9 to 17 Years
V501 Phase II Immunogenicity Study in Females Aged 9 to 17 Years
The study evaluates the immunogenicity, safety and tolerability of V501 in preadolescent females
Inclusion Criteria:
Exclusion Criteria: